Release date: 2024-08-14 17:27:03 Article From: Lucius Laos Recommended: 110
Venetoclax reduces the viability of cancer cells by highly selectively inhibiting the function of the Bcl-2 protein. Venetoclax has a low effect on platelets and has been approved for the treatment of a variety of hematologic tumors.
Understanding drug interactions to avoid unnecessary drug risks should be noted by both physicians and patients during medication treatment.
The use of venetoclax can lead to an increase in blood concentrations of P-gp substrate drugs, which may increase the risk of toxicity of these drugs. In order to reduce the harm caused by this interaction, it is recommended to avoid the simultaneous use of venetoclax and P-gp substrates as much as possible.
If it is true that the combination of these two drugs cannot be avoided, it is recommended to administer the P-gp substrate alone at least 6 hours before taking venetoclax to reduce the risk of toxicity.
Before taking the drug, it is important for patients to understand the precautions of the drug in detail to avoid the risks caused by blind medication.
During venetoclax treatment, patients are at significantly increased risk of infections, including potentially fatal and serious infections such as pneumonia and sepsis. These infections can affect the patient's treatment process and become life-threatening. Doctors need to pay special attention to the symptoms of infection and take effective anti-infective treatment measures in a timely manner.
There are currently no data on the safety and efficacy of live attenuated vaccines administered during or after venetoclax treatment. Patients are advised to avoid live attenuated vaccines during and around treatment with venetoclax until B-cell function is restored. Considering that the effectiveness of the vaccine may be affected by treatment, patients are advised to be cautious about vaccinations during this period and follow the doctor's guidance.
When using this drug, patients must be aware of some common adverse drug reactions:
During venetoclax treatment, people may feel extremely tired or lack energy, often requiring rest and adjustment of activity.
Swelling in the limbs or other parts of the body, usually due to fluid retention, may need to be managed with diuretics or dietary modifications.
[Warm tips] Patients should give feedback to the doctor in time about their physical discomfort and abnormal reactions, which will help the doctor to understand the patient's condition in a timely manner, and adjust the treatment plan or take necessary treatment measures according to the specific situation.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: